Welcome to LookChem.com Sign In|Join Free
  • or
4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

201530-57-6

Post Buying Request

201530-57-6 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

201530-57-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 201530-57-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,1,5,3 and 0 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 201530-57:
(8*2)+(7*0)+(6*1)+(5*5)+(4*3)+(3*0)+(2*5)+(1*7)=76
76 % 10 = 6
So 201530-57-6 is a valid CAS Registry Number.

201530-57-6Downstream Products

201530-57-6Relevant academic research and scientific papers

The clinically used iron chelator deferasirox is an inhibitor of epigenetic jumonjic domain-containing histone demethylases

Roatsch, Martin,Hoffmann, Inga,Abboud, Martine I.,Hancock, Rebecca L.,Tarhonskaya, Hanna,Hsu, Kuo-Feng,Wilkins, Sarah E.,Yeh, Tzu-Lan,Lippl, Kerstin,Serrer, Kerstin,Moneke, Isabelle,Ahrens, Theresa D.,Robaa, Dina,Wenzler, Sandra,Barthes, Nicolas P. F.,Franz, Henriette,Sippl, Wolfgang,Lassmann, Silke,Diederichs, Sven,Schleicher, Erik,Schofield, Christopher J.,Kawamura, Akane,Schüle, Roland,Jung, Manfred

, p. 1737 - 1750 (2019)

Fe(II)- A nd 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are "epigenetic eraser" enzymes involved in the regulation of gene expression and are emerging drug targets in oncology. We screened a set of clinically used iron chelators and report that they potently inhibit JMJD2A (KDM4A) in vitro. Mode of action investigations revealed that one compound, deferasirox, is a bona fide active site-binding inhibitor as shown by kinetic and spectroscopic studies. Synthesis of derivatives with improved cell permeability resulted in significant upregulation of histone trimethylation and potent cancer cell growth inhibition. Deferasirox was also found to inhibit human 2OG-dependent hypoxia inducible factor prolyl hydroxylase activity. Therapeutic effects of clinically used deferasirox may thus involve transcriptional regulation through 2OG oxygenase inhibition. Deferasirox might provide a useful starting point for the development of novel anticancer drugs targeting 2OG oxygenases and a valuable tool compound for investigations of KDM function.

Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

-

, (2008/06/13)

The use is described of 3,5-diphenyl-1,2,4-triazoles of the formula I in which R1-R5are as defined in the description. The compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 201530-57-6